How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?

Current Opinion in Neurology

Volumn 25, Issue 6, 2012, Pages 701-707

  Baloh, Robert H ^a,b  

^a Neuromuscular Division   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

amyotrophic lateral sclerosis; frontotemporal dementia; prion domain; protein aggregation; RNA metabolism

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIN D1; FUSED IN SARCOMA PROTEIN; MESSENGER RNA; RNA; SINGLE STRANDED DNA; TAR DNA BINDING PROTEIN; TAU PROTEIN; UBIQUILIN 2; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOPSY; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; FRONTOTEMPORAL DEMENTIA; GENE INTERACTION; GENE MUTATION; HUMAN; MOTONEURON; NONHUMAN; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; REVIEW; RNA METABOLISM; RNA STABILITY;

AMYOTROPHIC LATERAL SCLEROSIS; DNA-BINDING PROTEINS; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; RNA; RNA-BINDING PROTEIN FUS;

EID: 84870063066     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32835a269b     Document Type: Review

References (83)

1. Buratti E, Baralle FE. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci 2012; 37: 237-247.
2. Hanson KA, Kim SH, Tibbetts RS. RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. Wiley Interdiscip Rev RNA 2012; 3:265-285.
3. Corcia P, Valdmanis P, Millecamps S, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology 2012; 78:1519-1526.
4. Millecamps S, Salachas F, Cazeneuve C, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet 2010; 47:554-560.
5. Borghero G, Floris G, Cannas A, et al. A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiol Aging 2011; 32:2327; e2321-e2325.
6. Camdessanche JP, Belzil VV, Jousserand G, et al. Sensory and motor neuronopathy in a patient with the A382P TDP-43 mutation. Orphanet J Rare Dis 2011; 6:4.
7. Fujita Y, Ikeda M, Yanagisawa T, et al. Different clinical and neuropathologic phenotypes of familial ALS with A315E TARDBP mutation. Neurology 2011; 77:1427-1431.
8. Mosca L, Lunetta C, Tarlarini C, et al. Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiol Aging 2012; 33:1846; e1841-e1844.
9. Quadri M, Cossu G, Saddi V, et al. Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics 2011; 12:203-209.
10. Broustal O, Camuzat A, Guillot-Noel L, et al. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J Alzheimers Dis 2010; 22:765-769.
11. Yan J, Deng HX, Siddique N, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 2010; 75:807-814.
12. Chio A, Restagno G, Brunetti M, et al. Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. Neurobiol Aging 2009; 30:1272-1275.
13. DeJesus-Hernandez M, Kocerha J, Finch N, et al. De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat 2010; 31:E1377-E1389.
14. Baumer D, Hilton D, Paine SM, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010; 75:611-618.
15. Huang EJ, Zhang J, Geser F, et al. Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol 2010; 20:1069-1076.
16. Ito H, Fujita K, Nakamura M, et al. Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol 2011; 121:555-557.
17. Baborie A, Jaros E, Griffiths TD, et al. Frontotemporal lobar degeneration in a very young patient is associated with fused in sarcoma (FUS) pathological changes. Neuropathol Appl Neurobiol 2012; 38:101-104.
18. Conte A, Lattante S, Zollino M, et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul Disord 2012; 22:73-75.
19. Yamashita S, Mori A, Sakaguchi H, et al. Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. J Neurol 2012; 259:1039-1044.
20. Belzil VV, Langlais JS, Daoud H, et al. Novel FUS deletion in a patient with juvenile amyotrophic lateral sclerosis. Arch Neurol 2012. [Epub ahead of prin]
21. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323:1205-1208.
22. Zhang ZC, Chook YM. Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the fused in sarcoma protein (FUS). Proc Natl Acad Sci USA 2012; 109:12017-12021.
23. Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009; 132:2922-2931.
24. Lashley T, Rohrer JD, Bandopadhyay R, et al. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011; 134:2548-2564.
25. Baloh RH. TDP-43: the relationship between protein aggregation and neurodegeneration in ALS and FTLD. FEBS J 2011; 278:3538-3549.
26. Davidson YS, Robinson AC, Hu Q, et al. Nuclear carrier and RNA binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes. Neuropathol Appl Neurobiol 2012. doi: 10.1111/j.1365-2990.012.0127. [Epub ahead of print]
27. Colombrita C, Onesto E, Megiorni F, et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their posttranscriptional fate in motoneuron-like cells. J Biol Chem 2012; 287:15635-15647.
28. Hoell JI, Larsson E, Runge S, et al. RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol 2011; 18:1428-1431.
29. Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNAbinding proteins in cis to inhibit transcription. Nature 2008; 454:126-130. (Pubitemid 351934270)
30. Tan AY, Riley TR, Coady T, et al. TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. Proc Natl Acad Sci USA 2012; 109:6030-6035.
31. Buratti E, De Conti L, Stuani C, et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 2010; 277:2268-2281.
32. Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci USA 2012; 109:3347-3352.
33. Bentmann E, Neumann M, Tahirovic S, et al. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem 2012; 287:23079-23094.
34. Dewey CM, Cenik B, Sephton CF, et al. TDP-43 aggregation in neurodegeneration: are stress granules the key? Brain Res 2012; 1462:16-25.
35. Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol Cell 2009; 36:932-941.
36. Colombrita C, Zennaro E, Fallini C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem 2009; 111:1051-1061.
37. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE 2010; 5:e13250.
38. Fallini C, Bassell GJ, Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum Mol Genet 2012; 21:3703-3718.
39. Wang IF, Wu LS, Chang HY, Shen CK. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 2008; 105:797-806.
40. Aoki N, Higashi S, Kawakami I, et al. Localization of fused in sarcoma (FUS) protein to the postsynaptic density in the brain. Acta Neuropathol 2012; 124:383-394.
41. Johnson BS, Snead D, Lee JJ, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009; 284:20329-20339.
42. Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 2011; 5:1-5.
43. Furukawa Y, Kaneko K, Matsumoto G, et al. Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci 2009; 29:5153-5162.
44. Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell 2009; 136:1001-1004.
45. Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion 2011; 5:179-187.
46. Kato M, Han TW, Xie S, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 2012; 149:753-767.
47. Fuentealba RA, Udan M, Bell S, et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem 2010; 285:26304-26314.
48. Budini M, Buratti E, Stuani C, et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem 2012; 287:7512-7525.
49. Wang IF, Chang HY, Hou SC, et al. The self-interaction of native TDP-43C terminus inhibits its degradation and contributes to early proteinopathies. Nat Commun 2012; 3:766.
50. Kfoury N, Holmes BB, Jiang H, et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 2012; 287:19440-19451.
51. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011; 70:532-540.
52. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72:57-71.
53. Lanson NA Jr, Maltare A, King H, et al. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet 2011; 20:2510-2523.
54. Kabashi E, Bercier V, Lissouba A, et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoSGenet 2011; 7:e1002214.
55. Wang JW, Brent JR, Tomlinson A, et al. The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span. J Clin Invest 2011; 121:4118-4126.
56. Wegorzewska I, Baloh RH. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis 2011; 8:262-274.
57. Davidson Y, Kelley T, Mackenzie IR, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 2007; 113:521-533. (Pubitemid 46672598)
58. Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009; 106:18809-18814.
59. Igaz LM, Kwong LK, Lee EB, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 2011; 121:726-738.
60. Hicks GG, Singh N, Nashabi A, et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 2000; 24:175-179. (Pubitemid 30094720)
61. Kraemer BC, Schuck T, Wheeler JM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol 2010; 119:409-419.
62. Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem 2010; 285:6826-6834.
63. Wu LS, Cheng WC, Hou SC, et al. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis 2010; 48:56-62.
64. Dichmann DS, Harland RM. FUS/TLS orchestrates splicing of developmental regulators during gastrulation. Genes Dev 2012; 26:1351-1363.
65. Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis (ALS)-like phenotypes in mice. J Biol Chem 2012; 287:27335-27344.
66. Neumann M, Bentmann E, Dormann D, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 2011; 134:2595-2609.
67. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68:857-864.
68. Ju JS, Weihl CC. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy 2010; 6:283-285.
69. Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477:211-215.
70. Ju JS, Fuentealba RA, Miller SE, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009; 187:875-888.
71. Van Eersel J, Ke YD, Gladbach A, et al. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS ONE 2011; 6:e22850.
72. WuCH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012; 488:499-503.
73. Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 2007; 113:535-542. (Pubitemid 46672599)
74. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61:427-434. (Pubitemid 46878770)
75. Robertson J, Sanelli T, Xiao S, et al. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett 2007; 420:128-132. (Pubitemid 46818669)
76. Shan X, Vocadlo D, Krieger C. Mislocalization of TDP-43 in the G93A mutant SOD1 transgenic mouse model of ALS. Neurosci Lett 2009; 458:70-74.
77. Okamoto Y, Ihara M, Urushitani M, et al. An autopsy case of SOD1-related ALS with TDP-43 positive inclusions. Neurology 2011; 77:1993-1995.
78. Pokrishevsky E, Grad LI, Yousefi M, et al. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE 2012; 7:e35050.
79. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245-256.
80. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:257-268.
81. Mackenzie IR. The neuropathology of FTD associated with ALS. Alzheimer Dis Assoc Disord 2007; 21:S44-S49.
82. Stewart H, Rutherford NJ, Briemberg H, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol 2012; 123:409-417.
83. Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol 2010; 67:291-300.